Pharmacokinetics and first-pass elimination of metoprolol in rats: Contribution of intestinal first-pass extraction to low bioavailability of metoprolol

Xenobiotica

Volumn 41, Issue 3, 2011, Pages 243-251

  Yoon, In Soo ^a   Choi, Min Koo ^b   Kim, Jung Sun ^c   Shim, Chang Koo ^a   Chung, Suk Jae ^a   Kim, Dae Duk ^a  

^a Seoul National University   (South Korea)

^b Dankook University   (South Korea)

^c Dongseo University   (South Korea)

Author keywords

intestinal and hepatic first pass extraction; Metoprolol; pharmacokinetics; rats

Indexed keywords

METOPROLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSOME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; METOPROLOL; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

RATTUS;

EID: 79951845514     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.538090     Document Type: Article

References (25)

1. Boralli VB, Coelho EB, Lanchote VL. (2009). Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats. Chirality 21:886-893.
2. Borg KO, Fellenius E, Johansson R, Wallborg M. (1975). Pharmacokinetic studies of metoprolol-(3-h) in the rat and the dog. Acta Pharmacol Toxicol (Copenh) 36(Suppl. 5):104-115.
3. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686. (Pubitemid 44200529)
5. Cerqueira PM, Coelho EB, Geleilete TJ, Goldman GH, Lanchote VL. (2005). Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. J Clin Pharmacol 45:1422-1433. (Pubitemid 41642446)
6. Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-2552. (Pubitemid 44726394)
7. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
8. Di Verniero CA, Silberman EA, Mayer MA, Opezzo JA, Taira CA, Höcht C. (2008). In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 51:532-541.
9. Du Souich P, Maurice H, Héroux L. (1995). Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits. Drug Metab Dispos 23:279-284.
10. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61-90.
11. Gertz M, Harrison A, Houston JB, Galetin A. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
12. Ha HR, Follath F. (2004). Metabolism of antiarrhythmics. Curr Drug Metab 5:543-571. (Pubitemid 39534497)
13. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. (1998). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499. (Pubitemid 28231503)
14. Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915-1924.
15. Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640. (Pubitemid 14070321)
16. Lennernäs H. (1998). Human intestinal permeability. J Pharm Sci 87:403-410. (Pubitemid 28175799)
17. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. (1999). Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 16:1199-1205. (Pubitemid 29393607)
18. Mizuma T. (2002). Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab Pharmacokinet 17:496-506.
19. Mizuma T, Tsuji A, Hayashi M. (2004). Does the well-stirred model assess the intestinal first-pass effect well? J Pharm Pharmacol 56:1597-1599. (Pubitemid 39602002)
20. Mostafavi SA, Foster RT. (2000). Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. Int J Pharm 202:97-102. (Pubitemid 30466234)
21. Okabe H, Higashi T, Ohta T, Hashimoto Y. (2004). Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation. Biol Pharm Bull 27:1422-1427. (Pubitemid 41701686)
22. Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83-103.
23. Tanabe H, Taira S, Taguchi M, Hashimoto Y. (2007). Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull 30:552-555. (Pubitemid 46355945)
24. Wang BO, Semple HA. (1997). Inhibition of metoprolol metabolism by amino acids in perfused rat livers. Insights into the food effect? Drug Metab Dispos 25:287-295. (Pubitemid 27120573)
25. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)